While inflation is moderating, some health-related costs are still climbing.
But drug companies are trying to stymie the effort with a raft of lawsuits.
The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.
Oncology experts say advances in cancer drugs have played a major role.
Some manufacturers are willing to tie drug price to performance.
It's the seventh such deal for the insurance giant, which is putting pressure on drug makers in an effort to keep costs down.
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
Combined, Shire and Baxalta expect 65 percent of total revenue to come from rare disease treatments.
The drug, administered once a month, helps ensure patient compliance.
Valeant is under scrutiny for its business practices.
